This review argues that are becoming important kidney-protective therapy for diabetic , especially alongside cardiovascular and metabolic benefits.
Evidence
The evidence is a narrative review of GLP-1RA kidney signals from cardiovascular outcomes trials, dedicated kidney studies, and guideline-relevant high-risk populations including type 2 diabetes, obesity, and cardiovascular disease.
Caveat
The review identifies unresolved evidence gaps for non-diabetic CKD, dual or triple agonists, and oral GLP-1RA efficacy.
Simplified
(CKD) incidence continues to rise along with obesity and diabetes, driving substantial medical, psychosocial, and economic burdens for patients. Beyond glycemic control and the recommended therapies of ACEI/ARB, SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a cornerstone therapy to benefit mortality, heart and kidney outcomes. The following review will discuss recent advances to our understanding of the kidney benefits of GLP1 agonism in high-risk populations, including patients with type 2 diabetes mellitus, obesity, those with established cardiovascular disease. Renal signals from cardiovascular outcomes trials disclosed less albuminuria and slower estimated glomerular filtration rate (eGFR) decline with GLP1RA therapy, often additive to sodium-glucose cotransporter-2 inhibition. Dedicated kidney studies now show semaglutide slows CKD progression and lowers mortality in diabetics with CKD, underscoring the relevance of new guidelines that recommend GLP1RA therapy for specific populations. Future priorities should include trials of GLP-1RA in non-diabetic patients with CKD, as well as further evaluation of dual or triple agonists (GLP-1/GIP/glucagon) and clarification of oral GLP1RA efficacy. Overall, GLP-1-based therapies represent a transformative strategy to improve weight, cardiovascular health, and kidney outcomes in diabetic CKD patients.
Key numbers
24%
Reduction in primary outcome events
Compared to placebo in patients with diabetes and .
18%
Reduction in major cardiovascular events
In patients with diabetes and .
9.4%
Percentage of patients prescribed GLP-1RA
In a cohort of patients with , type 2 diabetes, and cardiovascular disease.
Full Text
We can’t show the full text here under this license.
Outside the submitted work, SDN reported serving on end point adjudication committee for clinical trials sponsored by Alnylam, Intercept, Prokidney and Vertex, and consultant for AstraZeneca, Bayer, Boehringer Ingelheim, and Novartis; and receiving research funding from the Department of Veterans Affairs Health Services Research & Development and National Institutes of Health. K. Rajan, A. Jutley, and MW Holliday Jr report no conflicts of interest in this work.
